Clarametyx Biosciences

Clarametyx Biosciences is addressing the significant challenge of persistent and stubborn infections through an innovative technology platform targeting biofilms (the protective layers surrounding bacteria), thereby making immune responses or antibiotic interventions more effective. Based in Columbus, Ohio, the company is building a dynamic pipeline of immunostimulatory therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate antibody, CMTX-101, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia.